| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53eeaabc9f6365c261c12f48b88c6d72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4bb6c22d9b6c8c5ab3926f98ba512aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b68f9bf2f758c477bd74f81c256a56b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95c564097de19aae01c6674e6314d769 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D521-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 |
| filingDate |
1999-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d007059fe2ad1a053f0f436e727f5022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff25689bc61931d1aaf3b3c0c1c8ec10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_388444f9508dd160219f1500e0d1eb4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8e5e4f997675bb7a7356cc2becb2175 |
| publicationDate |
2000-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0027827-A1 |
| titleOfInvention |
Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
| abstract |
Novel oxazolidinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012511007-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003535072-A |
| priorityDate |
1998-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |